$5.67
5.81% today
Nasdaq, Sep 23, 10:00 pm CET
ISIN
US46124U1079
Symbol
IVA

Inventiva - ADR Stock price

$5.67
+1.01 21.54% 1M
+2.75 94.18% 6M
+3.53 164.95% YTD
+3.48 158.92% 1Y
+1.75 44.64% 3Y
-5.83 50.70% 5Y
-7.75 57.75% 10Y
-7.75 57.75% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.35 5.81%
ISIN
US46124U1079
Symbol
IVA
Industry

Key metrics

Basic
Market capitalization
$751.0m
Enterprise Value
$701.1m
Net debt
positive
Cash
$113.9m
Shares outstanding
95.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
69.2 | 28.6
EV/Sales
64.6 | 26.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-89.6%
Return on Equity
172.7%
ROCE
5,442.7%
ROIC
109.1%
Debt/Equity
-0.5
Financials (TTM | estimate)
Revenue
$10.9m | $26.2m
EBITDA
$-106.4m | $-91.8m
EBIT
$-113.2m | $-130.7m
Net Income
$-217.4m | $-91.2m
Free Cash Flow
$-101.8m
Growth (TTM | estimate)
Revenue
-47.4% | 141.9%
EBITDA
9.9% | 13.8%
EBIT
6.5% | -15.5%
Net Income
-66.8% | 58.0%
Free Cash Flow
-5.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-980.7% | -349.6%
EBIT
-1,043.1%
Net
-2,002.7% | -347.5%
Free Cash Flow
-937.8%
More
EPS
$-3.2
FCF per Share
$-1.1
Short interest
0.0%
Employees
116
Rev per Employee
$90.0k
Show more

Is Inventiva - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Inventiva - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Inventiva - ADR forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Inventiva - ADR forecast:

Buy
92%
Hold
8%

Financial data from Inventiva - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
11 11
47% 47%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
19% 19%
133%
- Research and Development Expense 104 104
18% 18%
957%
-106 -106
10% 10%
-981%
- Depreciation and Amortization 6.78 6.78
127% 127%
62%
EBIT (Operating Income) EBIT -113 -113
7% 7%
-1,043%
Net Profit -217 -217
67% 67%
-2,003%

In millions USD.

Don't miss a Thing! We will send you all news about Inventiva - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inventiva - ADR Stock News

Neutral
GlobeNewsWire
19 days ago
Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company's leadership will participate in the followin...
Neutral
GlobeNewsWire
about 2 months ago
Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and ...
Neutral
GlobeNewsWire
3 months ago
Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD,...
More Inventiva - ADR News

Company Profile

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Head office France
CEO Frédéric Cren
Employees 116
Founded 2011
Website inventivapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today